Bottom line: Microdosing sounds like a nice idea for a class of drugs with common side effects during the initiation/dose escalation phase of treatment
Approval (2017) FDA News Release (March 8th, 2024): FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight FDA News Release (August 15th, 2025): FDA Approves Treatment for Serious Liver Disease Known as MASH OZEMPIC (semaglutide) injection, for subcutaneous use
L-glutathione is a tripeptide consisting of the 3 amino acids glutamine, glycine and cysteine
Persistently high blood sugar may need dose review or stopping
Wu Y, Fan Y, Xue B, Luo L, Shen J, Zhang S, Jiang Y, Yin Z (2006) Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals